Fiche publication
Date publication
avril 2017
Journal
Clinical nuclear medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CHENARD Marie-Pierre
,
Pr NAMER Izzie-Jacques
,
Pr PROUST François
,
Dr BUND Caroline
Tous les auteurs :
Bund C, Heimburger C, Imperiale A, Lhermitte B, Chenard MP, Lefebvre F, Kremer S, Proust F, Namer IJ
Lien Pubmed
Résumé
Primary brain tumor grading is crucial to rapidly determine the therapeutic impact and prognosis of a brain tumor as well as the tumors' aggressiveness profile. On magnetic resonance imaging, high-grade tumors are usually responsible for blood -brain barrier breakdowns, which result in tumor enhancement. However, this is not always the case. The main objective of this study was to evaluate the diagnostic value of FDOPA PET in the assessment of primary brain tumor aggressiveness with no contrast enhancement on MRI.
Mots clés
Adult, Brain Neoplasms, diagnostic imaging, Dihydroxyphenylalanine, analogs & derivatives, Female, Glioma, diagnostic imaging, Humans, Magnetic Resonance Imaging, Male, Positron Emission Tomography Computed Tomography, Predictive Value of Tests, Radiopharmaceuticals
Référence
Clin Nucl Med. 2017 Apr;42(4):250-257
